JR Pharm·CK Exogen, Exosome Patent Material Agreement..."New Product Development in Cosmetics and Medical Devices"

From the left, Jeil Farm Manager Junho Jeong, Jeil Farm CEO Myunghoon Yoo, Miho Holdings CEO Hogil Song, CK Exogen CSO Jaewoo Lee.

[Asia Economy Reporter Lee Gwan-joo] Pharmaceutical wholesale company JR Pharm announced on the 28th that it has signed a business agreement with bio venture company CK Exogen and CK Exogen's sponsor Miho Holdings to manufacture products using patented exosome materials.

This agreement was made to develop cosmetic and medical device products together with JR Pharm, whose main business is pharmaceutical wholesale and cosmetics distribution, based on CK Exogen's patented technology for mass production of exosomes. According to the agreement, the two companies will cooperate in ▲ developing new products based on patented exosome materials ▲ supporting marketing activities after product development.

JR Pharm is focusing on developing products that can restore skin vitality through its total healthcare brand 'REVE:AM'. CK Exogen is mainly engaged in developing COVID-19 vaccines, arthritis treatments, and AIDS vaccines by dramatically improving the rarity of exosome extraction from cells.

A JR Pharm official said, “Through this agreement, the product development know-how of JR Pharm and CK Exogen's mass production technology of exosomes will come together to introduce cosmetics and medical devices that are more easily accessible to general consumers,” adding, “CK Exogen plans to lead the related market not only through exosome research but also through product manufacturing.”

This content was produced with the assistance of AI translation services.